Biosimilars in Inflammatory Bowel Disease

• Published in: The American journal of gastroenterology Vol. 116; no. 1; pp. 45 - 56
• Main Authors: Buchner, Anna M, Schneider, Yecheskel, Lichtenstein, Gary R
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.01.2021
• Subjects: Adalimumab - economics; Adalimumab - therapeutic use; Autoimmune diseases; Biological products; Biosimilar Pharmaceuticals - economics; Biosimilar Pharmaceuticals - therapeutic use; Drug Costs; Drug Substitution; FDA approval; Gastroenterology; Health Expenditures; Health Services Accessibility; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Infliximab - economics; Infliximab - therapeutic use; Pharmacokinetics; Regulatory approval; Tumor Necrosis Factor Inhibitors - therapeutic use; Tumor necrosis factor-TNF; United States > US; Europe

Over the past 2 decades, biological therapy with monoclonal antibodies targeting tumor necrosis factor-α has become a cornerstone of treatment of patients with inflammatory bowel disease. Although clinically effective, the biological therapies remain expensive, and their availability and utilization...